<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops" lang="en">
<head>
<meta http-equiv="default-style" content="application/xhtml+xml; charset=utf-8"/>
<title>Brunner &#38; Suddarth&#8217;s Textbook of Medical-Surgical Nursing, 15e</title>
<link rel="stylesheet" type="text/css" href="style.css"/>
</head>
<body epub:type="bodymatter">
<div id="main_container">
<section epub:type="division">
<h4 class="h4" id="s424">Cancer Survivorship</h4>
<p class="nonindent">In the United States, there are currently an estimated 16.9 million adult cancer survivors; by 2030, that number is estimated to be 22.1 million (ACS, 2019f). Advances in cancer screening, treatment, and management of complications have contributed to a lengthened survival period for many, with long-term survival becoming possible for many patients. <em>Cancer survivorship</em> has been defined as the period from cancer diagnosis through the remaining years of life and focuses on the health and life of a person beyond diagnostic and treatment phases. Although individuals vary and many types of cancers and treatments exist, the acute, long-term, and late effects of cancer and its treatment may have multiple long-term physical, cognitive, psychological, social, and financial consequences that can impact activities of daily living, ultimately affecting quality of life (ACS, 2019f).</p>
<p class="indent">Survivorship care is often based on expert opinion and experience rather than on evidence-based practices. Knowledge regarding survivorship concerns continues to evolve. The Institute of Medicine has identified four components of survivorship care, the period that follows primary treatment for cancer and lasts until end of life. In addition to a summary of prior diagnosis and treatment, survivorship care includes monitoring and treatment for late effects related to disease and prior treatments, physical and vocational rehabilitation, psychosocial support and counseling as necessary, surveillance and screening for new and recurrent cancer, and coordination between specialists and primary care providers to ensure that all of the survivor&#x2019;s needs are met (<a href="#bib925">Hewitt, Greenfield, &#x0026; Stovall, 2006</a>) (see <a href="#tt12-12">Table&#x00A0;12-12</a>). Advocacy organizations across the country have recommended that a survivorship <span epub:type="pagebreak" id="page360" title="360"></span>care plan be provided to all patients with cancer and their primary provider at the completion of treatment. The survivorship care plan includes a summary of cancer diagnosis, treatment, recommendations for follow-up care, including approaches to treat symptoms, rehabilitative needs, monitoring for late effects, and surveillance and screening for new and recurrent cancer. Referrals for specific services such as lymphedema therapy, chronic pain management, and genetic counseling are also provided. Nurses assist in the development of the survivorship care plan and provide education and care for cancer survivors. Nurses, other health care providers, public health professionals, and patient advocates design and conduct research to identify needs of cancer survivors and evidence-based approaches to care.</p>
<div class="table">
<table class="tbo" id="tt12-12">
<colgroup>
<col style="width:20%"></col>
<col style="width:80%"></col>
</colgroup>
<tr>
<td class="tdnum"><p class="tnum"><strong>TABLE&#x00A0;12-12</strong></p></td>
<td><p class="tcaption">Components of Survivorship Care</p></td>
</tr>
</table>
<table class="table">
<tr><td class="thead"><p class="T2">Component</p></td>
<td class="thead"><p class="T2">Examples of Care</p></td></tr>
<tr><td class="td1"><p class="tbodyleft">Prevention and detection of new and recurrent cancer</p></td>
<td class="td1"><p class="tbodyleft">Mammography (per ACS guidelines)</p>
<p class="tbodyleft">Papanicolaou (Pap) smears (per ACS guidelines)</p>
<p class="tbodyleft">Smoking cessation programs</p>
<p class="tbodyleft">Nutrition counseling</p></td></tr>
<tr><td class="td2_line"><p class="tbodyleft">Surveillance for cancer spread, recurrence, or second cancers</p></td>
<td class="td2_line"><p class="tbodyleft">Colonoscopy post colon cancer</p>
<p class="tbodyleft">Mammography post breast cancer</p>
<p class="tbodyleft">Liver function tests post colon cancer</p>
<p class="tbodyleft">Prostate-specific antigen post prostate cancer</p></td></tr>
<tr><td class="td1_line"><p class="tbodyleft">Intervention for consequences of cancer and its treatments</p></td>
<td class="td1_line"><p class="tbodyleft">Lymphedema therapy</p>
<p class="tbodyleft">Pain management</p>
<p class="tbodyleft">Enterostomal therapy</p>
<p class="tbodyleft">Fertility care</p>
<p class="tbodyleft">Psychosocial support or counseling</p>
<p class="tbodyleft">Reconstructive surgery</p></td></tr>
<tr><td class="td2_line"><p class="tbodyleft">Coordination between specialists and primary providers to meet health needs</p></td>
<td class="td2_line"><p class="tbodyleft">Care for comorbidities (e.g., diabetes)</p>
<p class="tbodyleft">Influenza vaccination</p>
<p class="tbodyleft">Bone densitometry</p>
<p class="tbodyleft">Monitoring for chemotherapy induced cardiotoxicity</p></td></tr>
</table>
<p class="tablesource">ACS, American Cancer Society.</p>
<p class="tablesource">Adapted from Hewitt, M., Greenfield, S., &#x0026; Stovall, E. (Eds.). (2006). <em>From cancer patient to cancer survivor: Lost in translation</em>. Washington, DC: Institute of Medicine and National Research Council, National Academies Press. Components of survivorship care provided by the Institute of Medicine report on cancer survivorship.</p>
</div>
<h5 class="h5" id="s425">Providing Care to the Patient with Advanced Cancer</h5>
<p class="nonindent">The patient with advanced cancer needs to be monitored for oncologic emergencies and have appropriate treatment should emergencies occur. These patients may have end-of-life and palliative care needs that must be addressed.</p>
<h6 class="h6">Providing Care in Oncologic Emergencies</h6>
<p class="nonindent"><a href="#tt12-13">Table&#x00A0;12-13</a> discusses select nursing and medical care of oncologic emergencies.</p>
<p class="indent">As a result of advances in all aspects of cancer care, it is more common that individuals are living with cancer that has advanced beyond the original site of development to regional or distant sites. Patients with advanced cancer are likely to experience many of the problems described previously, although more often and to a greater degree. Symptoms of pain, anorexia, weight loss, CACS, fatigue, and impaired functional status and mobility make patients more susceptible to depressive symptoms, skin breakdown, fluid and electrolyte imbalances, and infection.</p>
<p class="indent">Treatment for the patient with advanced cancer is likely to be palliative rather than curative, with an emphasis on prevention and appropriate management of pain. The use of long-acting analgesic agents at set intervals, rather than on an &#x201C;as needed&#x201D; basis, is recommended in addressing pain management. Working with the patient and family, as well as with other health care providers, to manage pain is essential to increase the patient&#x2019;s comfort and offer some sense of control. Other medications (e.g., sedatives, tranquilizers, muscle relaxants, antiemetics) are added to assist in palliating additional symptoms and promoting quality of life.</p>
<div class="table">
<table class="tbo" id="tt12-13">
<colgroup>
<col style="width:20%"></col>
<col style="width:80%"></col>
</colgroup>
<tr>
<td class="tdnum"><p class="tnum"><strong>TABLE&#x00A0;12-13</strong></p></td>
<td><p class="tcaption">Oncologic Emergencies: Manifestations and Management</p></td>
</tr>
</table>
<table class="table">
<tr><td class="thead"><p class="T2">Oncologic Emergency</p></td>
<td class="thead"><p class="T2">Clinical Manifestations and Diagnostic Findings</p></td>
<td class="thead"><p class="T2">Medical and Nursing Management</p></td></tr>
<tr><td class="td1"><p class="tbodyleft"><strong>Superior Vena Cava Syndrome (SVCS)</strong></p>
<p class="tbodyleft">Compression or invasion of the superior vena cava by tumor; enlarged lymph nodes; intraluminal thrombus that obstructs venous circulation; or drainage of the head, neck, arms, and thorax. Most often associated with lung cancer, SVCS is also associated with lymphoma, thymoma, and testicular cancers and mediastinal metastases from breast cancer. If untreated, SVCS may lead to cerebral anoxia (because not enough oxygen reaches the brain), laryngeal edema, bronchial obstruction, and death.</p></td>
<td class="td1"><p class="tbodyleft"><strong>Clinical Manifestations:</strong></p>
<p class="tbodyleft">Gradually or suddenly impaired venous drainage giving rise to: progressive dyspnea (shortness of breath), cough, hoarseness, chest pain, and facial swelling</p>
<p class="tbodyleft">Edema of the neck, arms, hands, and thorax and reported sensation of skin tightness, difficulty swallowing, and stridor.</p>
<p class="tbodyleft">Possibly engorged and distended jugular, temporal, and arm veins.</p>
<p class="tbodyleft">Dilated thoracic vessels causing prominent venous patterns on the chest wall.</p>
<p class="tbodyleft">Increased intracranial pressure, associated visual disturbances, headache, and altered mental status</p></td>
<td class="td1"><p class="tbodyleft"><strong>Medical Management:</strong></p>
<p class="tbodyleft">Radiation therapy to shrink tumor or enlarged lymph nodes and relieve symptoms.</p>
<p class="tbodyleft">Chemotherapy for sensitive cancers (e.g., lymphoma, small cell lung cancer) or when the mediastinum has been irradiated to maximum tolerance.</p>
<p class="tbodyleft">Anticoagulant or thrombolytic therapy for central venous catheter&#x2013;related intraluminal thrombosis.</p>
<p class="tbodyleft">Percutaneously placed intravascular stents may be priority consideration rather than surgery unless symptoms are rapidly progressing.</p>
<p class="tbodyleft">Supportive measures such as oxygen therapy, corticosteroids, and diuretics (in cases of fluid overload).</p></td></tr>
<tr><td class="td1"></td><td class="td1">
<p class="tbodyleft"><strong>Diagnostic Findings:</strong></p>
<p class="tbodyleft">Diagnosis confirmed by:</p>
<p class="tbodyleft">Clinical findings</p>
<p class="tbodyleft">Chest x-ray</p>
<p class="tbodyleft">Thoracic CT scan</p>
<p class="tbodyleft">Thoracic MRI</p>
<p class="tbodyleft">Venogram if intraluminal thrombosis is suspected</p></td>
<td class="td1">
<p class="tbodyleft"><strong>Nursing Management:</strong></p>
<p class="tbodyleft">Identify patients at risk for SVCS.</p>
<p class="tbodyleft">Provide patient and family education regarding signs and symptoms to report.</p>
<p class="tbodyleft">Monitor and report clinical manifestations of SVCS.</p>
<p class="tbodyleft">Monitor cardiopulmonary and neurologic status.</p>
<p class="tbodyleft">Avoid upper extremity venipuncture and blood pressure measurement; instruct patient to avoid tight or restrictive clothing and jewelry on fingers, wrist, and neck.</p>
<p class="tbodyleft">Facilitate breathing and drainage from upper portion of body by instructing patient to maintain some elevation of head and upper body with semi-Fowler position; avoid completely supine or prone position (this helps to promote comfort and reduce anxiety associated with dependent and progressive edema).</p>
<p class="tbodyleft">Promote energy conservation to minimize dyspnea.</p>
<p class="tbodyleft">Monitor the patient&#x2019;s fluid volume status; administer fluids cautiously to minimize edema.</p>
<p class="tbodyleft">Assess for thoracic radiation-related problems such as mucositis with resultant dysphagia (difficulty swallowing) and esophagitis.</p>
<p class="tbodyleft">Monitor for chemotherapy-related problems, such as myelosuppression.</p>
<p class="tbodyleft">Provide postoperative care as appropriate.</p></td></tr>
<tr><td class="td2_line">
<p class="tbodyleft"><span epub:type="pagebreak" id="page361" title="361"></span><strong>Spinal Cord Compression</strong></p>
<p class="tbodyleft">Most commonly caused by compression of the cord and its nerve roots by a metastatic paravertebral tumor that extends into the epidural space; vertebral bone metastasis leading to bone collapse and displacement impinging on the spinal cord or nerve roots; and less commonly, primary malignancy of the cord. May potentially lead to significant and permanent neurologic impairment associated with multiple physical, psychosocial consequences.</p>
<p class="tbodyleft">Most often associated with cancers that metastasize to the bone such as breast, lung, and prostate cancers and lymphoma. Also seen in nasopharyngeal cancer and multiple myeloma.</p>
<p class="tbodyleft">About 60% of spinal cord compressions occur at the thoracic level, 30% in the lumbosacral level, and 10% in the cervical and sacral regions. The prognosis depends on the severity and rapidity of onset.</p></td>
<td class="td2_line">
<p class="tbodyleft"><strong>Clinical Manifestations:</strong></p>
<p class="tbodyleft">Local inflammation, edema, venous stasis, and impaired blood supply to nerve tissues.</p>
<p class="tbodyleft">Local or radicular back or neck pain along the dermatomal areas innervated by the affected nerve root (e.g., thoracic radicular pain extends in a band around the chest or abdomen).</p>
<p class="tbodyleft">Pain exacerbated by movement, supine recumbent position, coughing, sneezing, or the Valsalva maneuver.</p>
<p class="tbodyleft">Neurologic dysfunction and related motor and sensory deficits (numbness, tingling, feelings of coldness in the affected area, inability to detect vibration, loss of positional sense).</p>
<p class="tbodyleft">Motor loss ranging from subtle weakness to flaccid paralysis.</p>
<p class="tbodyleft">Bladder or bowel dysfunction depending on level of compression (above S2, overflow incontinence; from S3 to S5, flaccid sphincter tone and bowel incontinence).</p></td>
<td class="td2_line">
<p class="tbodyleft"><strong>Medical Management:</strong></p>
<p class="tbodyleft">Radiation therapy to reduce tumor size and halt progression; corticosteroid therapy to decrease inflammation and swelling at the compression site.</p>
<p class="tbodyleft">Surgery to debulk tumor and stabilize the spine if symptoms progress despite radiation therapy or if vertebral fracture or bone fragments lead to additional nerve damage; surgery is also an option when the tumor is not radiosensitive or is located in an area that was previously irradiated.</p>
<p class="tbodyleft">Minimally invasive surgical procedures, referred to as vertebral augmentation, may be used for patients with vertebral fractures to attain stability of the bone, prevent nerve compression, and decrease pain. Procedures include:</p>
<p class="tbodyleft">Vertebroplasty: involves percutaneous injection of polymethyl methacrylate (PMMA), a bone cement filler, into the vertebral body.</p>
<p class="tbodyleft">Kyphoplasty: a balloon is inserted into the damaged vertebral body and then inflated to create a cavity within the bone that can be filled with bone cement. The balloon helps to compress the fracture fragments together as the cavity is created.</p></td></tr>
<tr><td class="td2"></td><td class="td2">
<p class="tbodyleft"><strong>Diagnostic Findings:</strong></p>
<p class="tbodyleft">Percussion tenderness at the level of compression; abnormal reflexes; and sensory and motor abnormalities.</p>
<p class="tbodyleft">MRI is a preferred diagnostic tool; may also utilize x-rays, bone scans, and CT scan.</p></td>
<td class="td2">
<p class="tbodyleft">Radiofrequency vertebral augmentation: similar to kyphoplasty; instead of the balloon, a small navigational cannula is inserted into the vertebra to create small pathways for cement. The cement is heated with radiofrequency to create an ultra-high viscosity that is thought to promote bone stability.</p>
<p class="tbodyleft">Chemotherapy as adjuvant to other local therapies for patients with chemosensitive cancers, such as lymphoma or small cell lung cancer.</p>
<p class="tbodyleft"><em>Note:</em> Despite treatment, patients with poor neurologic function before treatment are less likely to regain complete motor and sensory function; patients who develop complete paralysis usually do not regain all neurologic function.</p>
<p class="tbodyleft"><strong>Nursing Management:</strong></p>
<p class="tbodyleft">Perform ongoing assessment of neurologic function to identify existing and progressing dysfunction.</p>
<p class="tbodyleft">Control pain with pharmacologic and nonpharmacologic measures.</p>
<p class="tbodyleft">Prevent complications of immobility resulting from pain and decreased function (e.g., skin breakdown, urinary stasis, thrombophlebitis, decreased clearance of pulmonary secretions).</p>
<p class="tbodyleft">Maintain muscle tone by assisting with range-of-motion exercises in collaboration with physical and occupational therapists; patients with unstable vertebral fractures do not initiate physical therapy until spine stabilization procedures have been completed.</p>
<p class="tbodyleft">Institute intermittent urinary catheterization and bowel training programs for patients with bladder or bowel dysfunction.</p>
<p class="tbodyleft">Provide encouragement and support to the patient and family coping with pain and altered functioning, lifestyle, roles, and independence.</p>
<p class="tbodyleft">Institute appropriate referrals for home care and physical and occupational therapy. Provide patient and family education about pharmacologic and nonpharmacologic interventions</p></td></tr>
<tr><td class="td1_line">
<p class="tbodyleft"><span epub:type="pagebreak" id="page362" title="362"></span><strong>Hypercalcemia</strong></p>
<p class="tbodyleft">Hypercalcemia is a potentially life-threatening metabolic abnormality resulting when the calcium released from the bones is more than the kidneys can excrete or the bones can reabsorb.</p>
<p class="tbodyleft">It may result from production of cytokines, hormonal substances, and growth factors by cancer cells, or by the body in response to biochemical mediators produced by cancer cells, which lead to bone breakdown and calcium release. Occurs in about 20% of patients with cancer; most commonly seen in patients with multiple myeloma and cancers of the lung and breast.</p></td>
<td class="td1_line">
<p class="tbodyleft"><strong>Clinical Manifestations:</strong></p>
<p class="tbodyleft">Fatigue, weakness, confusion, decreased level of responsiveness, hyporeflexia, nausea, vomiting, constipation, ileus, polyuria (excessive urination), polydipsia (excessive thirst), dehydration, and arrhythmias.</p>
<p class="tbodyleft"><strong>Diagnostic Findings:</strong></p>
<p class="tbodyleft">Total serum calcium level &#x003E;10.4 mg/dL (2.6 mmol/L)</p>
<p class="tbodyleft">Ionized serum calcium &#x003E;1.29 mmol/L</p></td>
<td class="td1_line">
<p class="tbodyleft"><strong>Medical Management:</strong></p>
<p class="tbodyleft">Identify patients at risk for hypercalcemia and assess for signs and symptoms of hypercalcemia. Treatment of the underlying malignancy (e.g., chemotherapy, radiation therapy, hormone therapy, immunotherapy or targeted therapy). Reduce serum calcium levels: Oral hydration (3&#x2013;4 L of fluid daily unless contraindicated by existing renal or cardiac disease) or IV hydration followed by diuretics (forced diuresis). Avoid dietary supplements and medications that can increase serum calcium levels (e.g., thiazide diuretics, nonsteroidal anti-inflammatory drugs; and vitamins A and D, and calcium supplements). Bisphosphonate therapy may be indicated for the long-term management. Maintenance of nutritional intake without restricting normal calcium intake. Dietary and pharmacologic interventions such as stool softeners and laxatives for constipation. Antiemetic therapy for nausea and vomiting.</p>
<p class="tbodyleft"><strong>Nursing Management:</strong></p>
<p class="tbodyleft">Monitor closely for changes in mental status; fluid and electrolyte imbalances; and renal, gastrointestinal, cardiac dysfunction. Monitor treatment effectiveness and for the presence of side effects. Ensure proper hydration and monitor fluid and electrolyte balance closely. Educate patients who are at-risk and their families to recognize and report signs and symptoms of hypercalcemia. Encourage mobilization / weight-bearing activities, as tolerated, to limit bone resorption. Maintain patient safety and ensure comfort. Educate patient and families about prescribed management strategies.</p></td></tr>
<tr><td class="td2_line">
<p class="tbodyleft"><strong>Tumor Lysis Syndrome (TLS)</strong></p>
<p class="tbodyleft">Potentially fatal complication that occurs spontaneously or more commonly following radiation, immunotherapy, targeted therapy, or chemotherapy-induced cell destruction of large or rapidly growing cancers such as leukemia, lymphoma, and small cell lung cancer. The release of tumor intracellular contents (nuclei acids, electrolytes, and debris) leads to rapidly induced electrolyte imbalances&#x2014;hyperkalemia, hyperphosphatemia (leading to hypocalcemia), and hyperuricemia&#x2014;that can have life-threatening end-organ effects on the myocardium, kidneys, and central nervous system.</p></td>
<td class="td2_line">
<p class="tbodyleft"><strong>Clinical Manifestations:</strong></p>
<p class="tbodyleft">Clinical manifestations depend on the extent of metabolic abnormalities.</p>
<p class="tbodyleft"><em>Neurologic:</em> Fatigue, weakness, memory loss, altered mental status, muscle cramps, tetany, paresthesias (numbness and tingling), and seizures.</p>
<p class="tbodyleft"><em>Cardiac:</em> Elevated blood pressure, shortened QT complexes, widened QRS waves, altered T waves, arrhythmias, and cardiac arrest.</p>
<p class="tbodyleft"><em>Gastrointestinal</em>: Anorexia, nausea, vomiting, abdominal cramps, diarrhea, and increased bowel sounds</p>
<p class="tbodyleft"><em>Renal</em>: Flank pain, oliguria, anuria, kidney injury, and acidic urine pH.</p>
<p class="tbodyleft"><em>Other</em>: Gout, malaise, and pruritis.</p>
<p class="tbodyleft"><strong>Diagnostic Findings:</strong></p>
<p class="tbodyleft">Electrolyte imbalances identified by serum electrolyte measurement and urinalysis (see <a href="c10.xhtml">Chapter 10</a>); electrocardiogram to detect cardiac arrhythmias. Clinical TLS is diagnosed when &#x2265;1 of 3 conditions arise either 3 days prior to or 7 days after cytotoxic cancer therapy: acute kidney injury (defined as a rise in creatinine to &#x2265;1.5 times the upper limit of normal that is not attributable to medications, arrhythmias, and seizures).</p></td>
<td class="td2_line">
<p class="tbodyleft"><strong>Medical Management:</strong></p>
<p class="tbodyleft">To prevent kidney injury and restore electrolyte balance. Aggressive fluid hydration is initiated 24&#x2013;48 h before and after the initiation of cytotoxic therapy to increase urine volume and eliminate uric acid and electrolytes.</p>
<p class="tbodyleft">Diuresis with a loop diuretic or osmotic diuretic, if urine output is inadequate.</p>
<p class="tbodyleft">Allopurinol therapy to inhibit the conversion of nucleic acids to uric acid (oral or IV). Rasburicase may be used to convert already formed uric acid to allantoin, which is highly water soluble and eliminated in urine.</p>
<p class="tbodyleft">Administration of a cation-exchange resin, such as sodium polystyrene sulfonate to treat hyperkalemia by binding and eliminating potassium through the bowel.</p>
<p class="tbodyleft">Administration of IV sodium bicarbonate, hypertonic dextrose, and regular insulin temporarily shifts potassium into cells and lowers serum potassium levels if a rapid decrease in potassium is necessary.</p>
<p class="tbodyleft">Administration of phosphate-binding gels, such as aluminum hydroxide, to treat hyperphosphatemia by promoting phosphate excretion in the feces.</p>
<p class="tbodyleft">Hemodialysis when patients are unresponsive to the standard approaches for managing uric acid and electrolyte abnormalities.</p>
<p class="tbodyleft">Identify at-risk patients.</p>
<p class="tbodyleft">Institute essential preventive measures (e.g., fluid hydration, medications) as prescribed.</p>
<p class="tbodyleft">Assess patient for signs and symptoms of electrolyte imbalances.</p>
<p class="tbodyleft"><strong>Nursing Management:</strong></p>
<p class="tbodyleft">Monitor for signs and symptoms of TLS in patients who are at-risk (e.g., those with hematologic malignancies).</p>
<p class="tbodyleft">Monitor vital signs, laboratory values (i.e., electrolyte), fluid balance closely (i.e., daily weights, intakes and outputs), and cardiac status closely.</p>
<p class="tbodyleft">Educate patients and families about risk factors for TLS; teach about current treatments (e.g., hydration, dietary restrictions [e.g., potassium and phosphorous], and pharmacologic therapy); signs and symptoms of complications; and when to report symptoms indicating electrolyte disturbances to the provider.</p></td></tr>
</table>
<p class="tablesource">CT, computed tomography; IV, intravenous; MRI, magnetic resonance imaging.</p>
<p class="tablesource">Adapted from Kaplan, M. (Ed.). (2018). <em>Understanding and managing oncologic emergencies: A resource for nurses</em>. Pittsburgh, PA: Oncology Nursing Society; Rimmer, A., &#x0026; Yahalom, J. (2018). Superior vena cava syndrome. In DeVita, V. T., Lawrence, T. S., Rosenberg, S. A. (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins; Stein, S., &#x0026; Deshpande, H. A. (2018). Metabolic emergencies. In DeVita, V. T., Lawrence, T. S., Rosenberg, S. A. (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins; and Szerlip, N., Beeler, W. H., &#x0026; Spratt, D. E. (2018). Spinal cord compression. In DeVita, V.T., Lawrence, T. S., Rosenberg, S. A. (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
</div>
<div class="pagebreak_container"><span class="pagebreak">p. 362</span><div class="rule"></div><span id="page363" class="pagebreak" epub:type="pagebreak" title="363">p. 363</span></div>
<p class="indent">If the patient is a candidate for radiation therapy or surgical interventions to relieve pain or other symptoms, the potential benefits and risks of these procedures (e.g., percutaneous nerve block, cordotomy) are explained to the patient and family. Measures are taken to prevent complications that result from altered sensation, immobility, and changes in bowel and bladder function.</p>
<p class="indent">Weakness, altered mobility, fatigue, and inactivity typically increase with advanced cancer as a result of the disease, treatment, inadequate nutritional intake, or dyspnea. The nurse works with the patient and family to identify realistic goals and promote comfort. Measures include use of energy conservation methods to accomplish tasks and activities that the patient values most.</p>
<p class="indent">Efforts are made to provide the patient with as much control and independence as desired but with assurance that support and assistance are available when needed. In addition, health care teams work with the patient and family to ascertain and comply with the patient&#x2019;s wishes about treatment methods and care as the terminal phase of illness and death approach.</p>
<h6 class="h6">Hospice</h6>
<p class="nonindent">The needs of patients with end-stage illness are best met by a comprehensive interdisciplinary specialty program that focuses on quality of life; palliation of symptoms; and provision of physical, psychosocial, and spiritual support for patients and families when cure and control of the disease are no longer possible. The concept of hospice best addresses these needs.</p>
<p class="indent">Hospice care is often delivered through coordination of specialty services provided by hospitals, home care programs, and the community. Patients need to be referred to hospice services in a timely fashion so that complex patient and family needs can be addressed. See <a href="c13.xhtml">Chapter 13</a> for detailed discussion of end-of-life care.</p>
<p class="reviewpH1">CRITICAL THINKING EXERCISES</p>
<div class="review">
<p class="reviewpNL1First"><span class="sblue">1</span> <img class="m" src="images/ebp.jpg" alt=""/> A 38-year-old man with early-onset colorectal cancer completed his first cycle of chemotherapy 2 days ago. He is now being admitted to the inpatient oncology unit with febrile neutropenia. What interventions and education should be considered for febrile neutropenia? What is the evidence for these interventions and education that you identified for febrile neutropenia? How strong is that evidence, and what criteria will you use to assess the strength of that evidence?</p>
<p class="reviewline"></p>
<p class="reviewpNL1Middle"><span class="sblue">2</span> <img class="m" src="images/pq.jpg" alt=""/> A 76-year-old woman, with a past medical history that is significant for cataracts, arthritis, and hypertension, was recently diagnosed with stage II breast cancer. She is being discharged today from the hospital following a bilateral mastectomy with several surgical drains in place. What are the priorities for the assessment of this patient to ensure her readiness for discharge to home? What will be your priorities when educating this patient for self-care?</p>
<p class="reviewline"></p>
<p class="reviewpNL1Last"><span class="sblue">3</span> <img class="m" src="images/ipc.jpg" alt=""/> You are caring for a 53-year-old man with diffuse large B-cell lymphoma who received CAR T&#x2013;cell therapy 2 days ago. How does CAR T&#x2013;cell therapy differ from conventional chemotherapy? What type of referrals might be appropriate for this patient? What members of the interprofessional health care team do you anticipate as being integral to the care of this patient?</p>
</div>
<p class="BIBLIOGRAPHYpTitle"><strong>REFERENCES</strong></p>
<p class="TOPICpBIBLIOGRAPHYpPARA">*Asterisk indicates nursing research.</p>
<p class="TOPICpBIBLIOGRAPHYpPARApIndent">**Double asterisk indicates classic reference.</p>
<p class="BIBLIOGRAPHYpREFMGROUPpTITLE">Books</p>
<p class="bib" id="bib920">Comerford, K. C., &#x0026; Durkin, M. T. (2020). <em>Nursing 2020 drug handbook</em>. Philadelphia, PA: Wolters Kluwer.</p>
<p class="bib" id="bib921">DeVita, V. T., Rosenberg S. A., &#x0026; Lawrence, T. S. (Eds.). (2018). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib922">Eliopoulos, C. (2021). <em>Gerontological nursing</em> (10th ed.). Philadelphia, PA: Wolters Kluwer.</p>
<p class="bib" id="bib923">Fischbach, F. T., &#x0026; Fischbach, M. A. (2018). <em>Fischbach&#x2019;s manual of laboratory and diagnostic tests</em> (10th ed.). Philadelphia, PA: Wolters Kluwer.</p>
<p class="bib" id="bib924">Halperin, E. C., Wazer, D. E., Perez, C. A., et al. (Eds.). (2019). <em>Perez and Brady&#x2019;s principles and practice of radiation oncology</em> (6th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib925">**Hewitt, M., Greenfield, S., &#x0026; Stovall, E. (Eds.). (2006). <em>From cancer patient to cancer survivor: Lost in translation</em>. Washington, DC: Institute of Medicine and National Research Council, National Academies Press.</p>
<p class="bib" id="bib926">Jameson, J. L., Fauci, A. S., Kasper, D. L., et al. (Eds.). (2018). <em>Harrison&#x2019;s principles of internal medicine</em> (20th ed.). New York: McGraw Hill Education.</p>
<p class="bib" id="bib927">Jansen, C. (2017). Cognitive changes. In J. Eggert (Ed.). <em>Cancer basics</em> (2nd ed.). Pittsburg, PA: Oncology Nursing Society.</p>
<p class="bib" id="bib928">Kaplan, M. (Ed.) (2018). <em>Understanding and managing oncologic emergencies: A resource for nurses</em>. Pittsburgh, PA: Oncology Nursing Society.</p>
<p class="bib" id="bib929">Mones, J. V., &#x0026; Soff, G. (2019). Management of thrombocytopenia in cancer patients. In <em>Thrombosis and hemostasis in cancer</em> (pp. 139&#x2013;150). Basel, Switzerland: Springer Publishing International.</p>
<p class="bib" id="bib930">Morgan, M. A., Ten Haken, R. K., &#x0026; Lawrence, T. S. (2018). Essentials of radiation therapy. In V. T. DeVita, S. A. Rosenberg, &#x0026; T. S. Lawrence (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib931">Norris, T. L. (2019). <em>Porth&#x2019;s pathophysiology: Concepts of altered health states</em> (10th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib932">Olsen, M. M., LeFebvre, K. B., &#x0026; Brassil, K. (Eds.). (2019). <em>Chemotherapy and immunotherapy guidelines and recommendations for practice</em>. Pittsburgh, PA: Oncology Nursing Society.</p>
<p class="bib" id="bib933">Palmore, T. N., Parta, M., Cuellar-Rodriguez, J., et al. (2018). Infections in the cancer patient. In V. T. DeVita, S. A. Rosenberg, &#x0026; T. S. Lawrence (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib934">Rimmer, A., &#x0026; Yahalom, J. (2018). Superior vena cava syndrome. In V. T. DeVita, S. A. Rosenberg, &#x0026; T. S. Lawrence (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib935">Stein, S., &#x0026; Deshpande, H. A. (2018). Metabolic emergencies. In V. T. DeVita, S. A. Rosenberg, &#x0026; T. S. Lawrence (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib936">Szerlip, N., Beeler, W. H., &#x0026; Spratt, D. E. (2018). Spinal cord compression. In V. T. DeVita, S. A. Rosenberg, &#x0026; T. S. Lawrence (Eds.). <em>Cancer: Principles &#x0026; practice of oncology</em> (11th ed.). Philadelphia, PA: Lippincott Williams &#x0026; Wilkins.</p>
<p class="bib" id="bib937">Yarbro, C. H., Wujcik, D., &#x0026; Gobel, B. H. (2018). <em>Cancer nursing: Principles and practice</em>. Burlington, MA: Jones &#x0026; Bartlett Publishers.</p>
<p class="BIBLIOGRAPHYpREFMGROUPpTITLE"><span epub:type="pagebreak" id="page364" title="364"></span>Journals and Electronic Documents</p>
<p class="bib" id="bib938">Akthar, A. S., Liao, C., Eggener, S. E., et al. (2019). Patient-reported outcomes and late toxicity after postprostatectomy intensity-modulated radiation therapy. <em>European Urology</em>, <em>8404</em>, E1&#x2013;E7.</p>
<p class="bib" id="bib939">Almont, T., Farsi, F., Krakowski, I., et al. (2019). Sexual health in cancer: The results of a survey exploring practices, attitudes, knowledge, communication, and professional interactions in oncology healthcare providers. <em>Supportive Care in Cancer</em>, <em>27</em>(3), 887&#x2013;894.</p>
<p class="bib" id="bib940">American Cancer Society (ACS). (2018). American Cancer Society Guidelines for the early detection of cancer. Retrieved on 7/14/2019 at: <a href="http://www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html">www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html</a></p>
<p class="bib" id="bib941">American Cancer Society (ACS). (2019a). Cancer facts and figures 2019. Retrieved on 7/5/2019 at: <a href="http://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html">www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html</a></p>
<p class="bib" id="bib942">American Cancer Society (ACS). (2019b). What causes cancer? Retrieved on 7/6/2019 at: <a href="http://www.cancer.org/cancer/cancer-causes.html">www.cancer.org/cancer/cancer-causes.html</a></p>
<p class="bib" id="bib943">American Cancer Society (ACS). (2019c). Ultraviolet (UV) radiation sun and other types of radiation. Retrieved on 7/7/2019 at: <a href="http://www.cancer.org/cancer/cancer-causes/radiation-exposure/uv-radiation.html">www.cancer.org/cancer/cancer-causes/radiation-exposure/uv-radiation.html</a></p>
<p class="bib" id="bib944">American Cancer Society (ACS). (2019d). Tobacco and cancer. Retrieved on 7/8/2019 at: <a href="http://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer.html">www.cancer.org/cancer/cancer-causes/tobacco-and-cancer.html</a></p>
<p class="bib" id="bib945">American Cancer Society (ACS). (2019e). Known and probable human carcinogens. Retrieved on 7/22/2019 at: <a href="http://www.cancer.org/cancer/cancer-causes/general-info/known-and-probable-human-carcinogens.html">www.cancer.org/cancer/cancer-causes/general-info/known-and-probable-human-carcinogens.html</a></p>
<p class="bib" id="bib946">American Cancer Society (ACS). (2019f). Cancer treatment and survivorship: Facts and figures 2019&#x2013;2021. Retrieved on 7/10/2019 at: <a href="http://www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html">www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html</a></p>
<p class="bib" id="bib947">American Cancer Society (ACS). (2019g). Cancer immunotherapy. Retrieved on 7/15/2019 at: <a href="http://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy.html">www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy.html</a></p>
<p class="bib" id="bib948">American Cancer Society (ACS). (2019h). Intravesical therapy for bladder cancer. Retrieved on 7/20/2019 at: <a href="http://www.cancer.org/cancer/bladder-cancer/treating/intravesical-therapy.html">www.cancer.org/cancer/bladder-cancer/treating/intravesical-therapy.html</a></p>
<p class="bib" id="bib949">American Cancer Society (ACS). (2019i). ACS guidelines on nutrition and physical activity for cancer. Retrieved on 9/28/2018 at: <a href="https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html">https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html</a></p>
<p class="bib" id="bib950">Amin, M. B., Greene, F. L., Edge, S. B., et al. (2017). The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more &#x201C;personalized&#x201D; approach to cancer staging. <em>CA: A Cancer Journal for Clinicians</em>, <em>67</em>(2), 93&#x2013;99.</p>
<p class="bib" id="bib951">Anderson, K., &#x0026; Latchford, T. (2019). Associated toxicities: Assessment and management related to CAR T cell therapy. <em>Clinical Journal of Oncology Nursing</em>, <em>23</em>(2-suppl.), 13&#x2013;19.</p>
<p class="bib" id="bib952">Armenian, S., &#x0026; Bhatia, S. (2018). Predicting and preventing anthracycline-related cardiotoxicity. <em>American Society of Clinical Oncology Educational Book</em>, <em>38</em>, 3&#x2013;12.</p>
<p class="bib" id="bib953">Barton-Burke, M., Ciccolini, K., Mekas, M., et al. (2017). Dermatologic reactions to targeted therapy: A focus on epidermal growth factor receptor inhibitors and nursing care. <em>Nursing Clinics</em>, <em>52</em>(1), 83&#x2013;113.</p>
<p class="bib" id="bib954">Bayer, V., Amaya, B., Baniewicz, D., et al. (2017). Cancer immunotherapy: An evidence-based overview and implications for practice. <em>Clinical Journal of Oncology Nursing</em>, <em>21</em>(2 Suppl), 13&#x2013;21.</p>
<p class="bib" id="bib955">Berger, K., Schopohl, D., Bollig, A., et al. (2018). Burden of oral mucositis: A systematic review and implications for future research. <em>Oncology Research and Treatment</em>, <em>41</em>(6), 399&#x2013;405.</p>
<p class="bib" id="bib956">Bishop, D. P., Cole, N., Zhang, T., et al. (2018). A guide to integrating immunohistochemistry and chemical imaging. <em>Chemical Society Reviews</em>, <em>47</em>(11), 3770&#x2013;3787.</p>
<p class="bib" id="bib957">Bowen, J. M., Gibson, R. J., Coller, J. K., et al. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <em>Supportive Care in Cancer</em>, <em>27</em>(10), 4011&#x2013;4012.</p>
<p class="bib" id="bib958">Cannioto, R., Etter, J. L., Guterman, L. B., et al. (2017). The association of lifetime physical inactivity with bladder and renal cancer risk: A hospital-based case-control analysis. <em>Cancer Epidemiology</em>, <em>49</em>, 24&#x2013;29.</p>
<p class="bib" id="bib959">Cannioto, R., Etter, J. L., LaMonte, M. J., et al. (2018). Lifetime physical inactivity is associated with lung cancer risk and mortality. <em>Cancer Treatment and Research Communications</em>, <em>14</em>, 37&#x2013;45.</p>
<p class="bib" id="bib960">Centers for Disease Control and Prevention (CDC). (2017). NIOSH chemical carcinogen policy: DHHS (NIOSH) publication number 2017-100. Retrieved on 7/13/2019 at: <a href="http://www.cdc.gov/niosh/docs/2017-100/default.html">www.cdc.gov/niosh/docs/2017-100/default.html</a></p>
<p class="bib" id="bib961">Centers for Disease Control and Prevention (CDC). (2018). Hepatitis B vaccine saves lives. Retrieved on 7/28/2019 at: <a href="http://www.cdc.gov/features/hepatitisb/index.html">www.cdc.gov/features/hepatitisb/index.html</a></p>
<p class="bib" id="bib962">Centers for Disease Control and Prevention (CDC). (2019). Smoking and tobacco use. Retrieved on 7/5/2019 at: <a href="http://www.cdc.gov/tobacco/data_statistics/fact_sheets/secondhand_smoke/health_effects/index.htm">www.cdc.gov/tobacco/data_statistics/fact_sheets/secondhand_smoke/health_effects/index.htm</a></p>
<p class="bib" id="bib963">Chagpar, A. B. (2018). Contralateral prophylactic mastectomy. UpToDate. Waltham, MA. Retrieved on 7/17/2019 at: <a href="http://www.uptodate.com/contents/contralateral-prophylactic-mastectomy">www.uptodate.com/contents/contralateral-prophylactic-mastectomy</a></p>
<p class="bib" id="bib964">Chen, P. H., Mahmood, Q., Mariottini, G. L., et al. (2017). Adverse health effects of betel quid and the risk of oral and pharyngeal cancers. <em>BioMed Research International</em>, <em>2017</em>, 1&#x2013;25.</p>
<p class="bib" id="bib965">Chen, W. Y. (2019). Factors that modify breast cancer risk in women. UpToDate, Waltham, MA. Retrieved on 7/27/2019 at: <a href="http://www.uptodate.com/contents/factors-that-modify-breast-cancer-risk-in-women">www.uptodate.com/contents/factors-that-modify-breast-cancer-risk-in-women</a></p>
<p class="bib" id="bib966">*Corbitt, N., Harrington, J., &#x0026; Kendall, T. (2017). Putting evidence into practice: Prevention of bleeding. Retrieved on 7/23/2019 at: <a href="http://www.ons.org/pep/bleeding">www.ons.org/pep/bleeding</a></p>
<p class="bib" id="bib967">Deng, G., Yin, M., Chen, X., et al. (2020). Clinical determinants for fatality of 44,672 patients with COVID-19. <em>Critical Care</em>, <em>24</em>, 179&#x2013;181.</p>
<p class="bib" id="bib968">DeSantis, C. E., Miller, K. D., Goding Sauer, A., et al. (2019). Cancer statistics for African Americans, 2019. <em>CA: A Cancer Journal for Clinicians</em>, <em>69</em>(3), 211&#x2013;233.</p>
<p class="bib" id="bib969">Dickens, E., &#x0026; Ahmed, S. (2018). Principles of cancer treatment by chemotherapy. <em>Surgery (Oxford)</em>, <em>36</em>(3), 134&#x2013;138.</p>
<p class="bib" id="bib970">Divgi, C. (2018). The current state of radiopharmaceutical therapy. <em>Journal of Nuclear Medicine</em>, <em>59</em>(11), 1706&#x2013;1707.</p>
<p class="bib" id="bib971">**DuPen, A. R., DuPen, S., Hansberry, J., et al. (2000). An educational implementation of a cancer pain algorithm for ambulatory care. <em>Pain Management Nursing</em>, <em>1</em>(4), 116&#x2013;128.</p>
<p class="bib" id="bib972">Dusetzina, S. B., Huskamp, H. A., Winn, A. N., et al. (2018). Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity laws. <em>JAMA Oncology</em>, <em>4</em>(6), e173598.</p>
<p class="bib" id="bib973">Eilers, J. G., Asakura, Y., Blecher, C. S., et al. (2017). Putting evidence into practice: Mucositis. Retrieved on 7/7/2019 at: <a href="http://www.ons.org/pep/mucositis">www.ons.org/pep/mucositis</a></p>
<p class="bib" id="bib974">Eller, L. S., Lev, E. L., Yuan, C., et al. (2018). Describing self-care self-efficacy: Definition, measurement, outcomes, and implications. <em>International Journal of Nursing Knowledge</em>, <em>29</em>(1), 38&#x2013;48.</p>
<p class="bib" id="bib975">Fahy, B. N. (2019). Introduction: Role of palliative care for the surgical patient. <em>Journal of Surgical Oncology</em>, <em>120</em>(1), 5&#x2013;9.</p>
<p class="bib" id="bib976">Fritz, A., Percy, C., &#x0026; Jack, A. (2013). International classification of diseases for oncology (ICD-O)&#x2013;3rd edition, 1st revision. Retrieved at: <a href="https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf;jsessionid=60D66DA21C5A4BA7486F40A4DC258752?sequence=1">https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf;jsessionid=60D66DA21C5A4BA7486F40A4DC258752?sequence=1</a></p>
<p class="bib" id="bib977">Ginsburg, G. S., &#x0026; Phillips, K. A. (2018). Precision medicine: From science to value. <em>Health Affairs</em>, <em>37</em>(5), 694&#x2013;701.</p>
<p class="bib" id="bib978">Gosselin, T., Beamer, L., Ciccolini, K., et al. (2017). Putting evidence into practice: Radiodermatitis. Retrieved on 6/28/2019 at: <a href="http://www.ons.org/pep/radiodermatitis">www.ons.org/pep/radiodermatitis</a></p>
<p class="bib" id="bib979">Hanna, J., Blazer, D. G., &#x0026; Mosca, P. J. (2012). Overview of palliative surgery: principles and priorities. <em>J Palliative Care Med</em>, <em>2</em>(7), 1&#x2013;6.</p>
<p class="bib" id="bib980">Haryani, H., Fetzer, S. J., Wu, C. L., et al. (2017). Chemotherapy-induced peripheral neuropathy assessment tools: A systematic review. <em>Oncology Nursing Forum</em>, <em>44</em>(3), E111&#x2013;E123.</p>
<p class="bib" id="bib981">Hashim, D., Genden, E., Posner, M., et al. (2019). Head and neck cancer prevention: From primary prevention to impact of clinicians on reducing burden. <em>Annals of Oncology</em>, <em>30</em>(5), 744&#x2013;756.</p>
<p class="bib" id="bib982">Henriksen, P. A. (2018). Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention. <em>Heart</em>, <em>104</em>(12), 971&#x2013;977.</p>
<p class="bib" id="bib983">Hermioni, A., Christina, M., Melanie, F., et al. (2019). Psychological considerations in hematopoietic stem cell transplantation. <em>Psychosomatics</em>, <em>60</em>(4), 331&#x2013;342.</p>
<p class="bib" id="bib984">Howell, D., Harth, T., Brown, J., et al. (2017). Self-management education interventions for patients with cancer: A systematic review. <em>Supportive Care in Cancer</em>, <em>25</em>(4), 1323&#x2013;1355.</p>
<p class="bib" id="bib985">Huo, D., Anderson, D., Palmer, J. R., et al. (2017). Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. <em>Gynecologic Oncology</em>, <em>146</em>(3), 566&#x2013;571.</p>
<div class="pagebreak_container"><span class="pagebreak">p. 364</span><div class="rule"></div><span id="page365" class="pagebreak" epub:type="pagebreak" title="365">p. 365</span></div>
<p class="bib" id="bib986">Islami, F., Goding Sauer, A., Miller, K. D., et al. (2018). Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. <em>CA: A Cancer Journal for Clinicians</em>, <em>68</em>(1), 31&#x2013;54.</p>
<p class="bib" id="bib987">Jang, W. S., Kim, M. S., Jeong, W. S., et al. (2018). Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? <em>BJU International</em>, <em>121</em>(2), 225&#x2013;231.</p>
<p class="bib" id="bib988">Jatoi, A., &#x0026; Kelly, D. (2019). The role of parenteral and enteral/oral nutritional support in patients with cancer. UpToDate. Waltham, MA. Retrieved on 7/19/2019 at: <a href="http://www.uptodate.com/contents/the-role-of-parenteral-and-enteral-oral-nutritional-support-tients-with-cancer">www.uptodate.com/contents/the-role-of-parenteral-and-enteral-oral-nutritional-support-`tients-with-cancer</a></p>
<p class="bib" id="bib989">Johns Hopkins University &#x0026; Medicine Coronavirus Resource Center. (2020). Maps and trends: Mortality analysis. Retrieved on 6/12/2020 at: <a href="http://coronavirus.jhu.edu/data/mortality">coronavirus.jhu.edu/data/mortality</a></p>
<p class="bib" id="bib990">Kays, L. B. (2018). Advancements come with a cost: Oral chemotherapy parity laws. Retrieved on 6/28/2019 at: <a href="http://www.pharmacytimes.com/publications/issue/2018/february2018/advancements-come-with-a-cost-oral-chemotherapy-parity-laws">www.pharmacytimes.com/publications/issue/2018/february2018/advancements-come-with-a-cost-oral-chemotherapy-parity-laws</a></p>
<p class="bib" id="bib991">Kessels, E., Husson, O., &#x0026; Van der Feltz-Cornelis, C. M. (2018). The effect of exercise on cancer-related fatigue in cancer survivors: A systematic review and meta-analysis. <em>Neuropsychiatric Disease and Treatment</em>, <em>14</em>, 479&#x2013;494.</p>
<p class="bib" id="bib992">Krengli, M., Pisani, C., Deantonio, L., et al. (2017). Intraoperative radiotherapy in gynaecological and genitourinary malignancies: Focus on endometrial, cervical, renal, bladder and prostate cancers. <em>Radiation Oncology</em>, <em>12</em>(1), 2&#x2013;10.</p>
<p class="bib" id="bib993">Krishnasamy, K., Yoong, T. L., Chan, C. M., et al. (2017). Identifying malnutrition. <em>Clinical Journal of Oncology Nursing</em>, <em>21</em>(1), E23&#x2013;E29.</p>
<p class="bib" id="bib994">Kuderer, N. M., Choueiri, T. K., Shah, D. P., et al. (2020). Clinical impact of COVID-19 on patients with cancer (CC-19): A cohort study. <em>Lancet</em>, <em>6736</em>(20), 31187-9.</p>
<p class="bib" id="bib995">Lamprecht, M., &#x0026; Dansereau, C. (2019). CAR T cell therapy. <em>Clinical Journal of Oncology Nursing</em>, <em>23</em>(2), 6&#x2013;10.</p>
<p class="bib" id="bib996">Lazarev, S., Gupta, V., Ghiassi-Nejad, Z., et al. (2018). Premature discontinuation of curative radiation therapy: Insights from head and neck irradiation. <em>Advances in Radiation Oncology</em>, <em>3</em>(1), 62&#x2013;69.</p>
<p class="bib" id="bib997">Lipari, R. N., &#x0026; Van Horn, S. L. (2017). Trends in smokeless tobacco use and initiation: 2002 to 2012. <em>The Center for Behavioral Health Statistics and Quality Report</em>. Retrieved on 6/18/2019 at: <a href="http://www.samhsa.gov/data/sites/default/files/report_2740/ShortReport-2740.html">www.samhsa.gov/data/sites/default/files/report_2740/ShortReport-2740.html</a></p>
<p class="bib" id="bib998">Lunn, R. M., Jahnke, G. D., &#x0026; Rabkin, C. S. (2017). Tumour virus epidemiology. <em>Philosophical Transactions of the Royal Society B: Biological Sciences</em>, <em>372</em>(1732), 1&#x2013;11.</p>
<p class="bib" id="bib999">Mainardi, S., Mulero-S&#x00E1;nchez, A., Prahallad, A., et al. (2018). SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. <em>Nature Medicine</em>, <em>24</em>(7), 961&#x2013;967.</p>
<p class="bib" id="bib1000">Mattox, T. W. (2017). Cancer cachexia: Cause, diagnosis, and treatment. <em>Nutrition in Clinical Practice</em>, <em>32</em>(5), 599&#x2013;606.</p>
<p class="bib" id="bib1001">*Menonna-Quinn, D., Polovich, M., &#x0026; Marshall, B. (2019). Personal protective equipment: Evaluating usage among inpatient and outpatient oncology nurses. <em>Clinical Journal of Oncology Nursing</em>, <em>23</em>(3), 260&#x2013;265.</p>
<p class="bib" id="bib1002">Merchan, J. R., Jhaveri, K. D., Berns, J. S., et al. (2017). Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents. UpToDate. Waltham, MA. Retrieved on 6/29/2019 at: <a href="http://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents">www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents</a></p>
<p class="bib" id="bib1003">*Miaskowski, C. A., Brant, J. M., Caldwell, P., et al. (2017). Putting evidence into practice: Chronic pain. Retrieved on 7/19/2019 at: <a href="http://www.ons.org/pep/chronic-pain">www.ons.org/pep/chronic-pain</a></p>
<p class="bib" id="bib1004">Miller, K. D., Goding Sauer, A., Ortiz, A. P., et al. (2018). Cancer statistics for Hispanics/Latinos, 2018. <em>CA: A Cancer Journal for Clinicians</em>, <em>68</em>(6), 425&#x2013;445.</p>
<p class="bib" id="bib1005">*Mitchell, S. A., Albrecht, T. A., Omar Alkaiyat, M., et al. (2017). Putting evidence into practice: Fatigue. Retrieved on 7/2/2019 at: <a href="http://www.ons.org/pep/fatigue">www.ons.org/pep/fatigue</a></p>
<p class="bib" id="bib1006">Mutahar, E., &#x0026; Al-Anazi, K. A. (2017). Engraftment syndrome: An updated review. <em>Journal of Stem Cell Biology and Transplantation</em>, <em>1</em>(3), E1&#x2013;E5.</p>
<p class="bib" id="bib1007">Natale, J. J. (2018). Overview of the prevention and management of CINV. <em>The American Journal of Managed Care</em>, <em>24</em>(18 Suppl), S391&#x2013;S397.</p>
<p class="bib" id="bib1008">National Cancer Institute (NCI). (2017). Obesity and cancer. Retrieved on 7/13/2019 at: <a href="http://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet">www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet</a></p>
<p class="bib" id="bib1009">National Cancer Institute (NCI). (2018). Menopausal hormone therapy and cancer. Retrieved on 7/7/2019 at: <a href="http://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/mht-fact-sheet">www.cancer.gov/about-cancer/causes-prevention/risk/hormones/mht-fact-sheet</a></p>
<p class="bib" id="bib1010">National Cancer Institute (NCI). (2019a). Cancer disparities. Retrieved on 7/4/2019 at: <a href="http://www.cancer.gov/about-cancer/understanding/disparities">www.cancer.gov/about-cancer/understanding/disparities</a></p>
<p class="bib" id="bib1011">National Cancer Institute (NCI). (2019b). Cancer genetics overview for health professionals. Retrieved on 7/3/2019 at: <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq">www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq</a></p>
<p class="bib" id="bib1012">National Cancer Institute (NCI). (2019c). Understanding cancer prognosis. Retrieved on 7/2/2019 at: <a href="http://www.cancer.gov/about-cancer/diagnosis-staging/prognosis">www.cancer.gov/about-cancer/diagnosis-staging/prognosis</a></p>
<p class="bib" id="bib1013">National Cancer Institute (NCI). (2019d). Targeted cancer therapies. Retrieved 7/17/2019 at: <a href="http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet">www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet</a></p>
<p class="bib" id="bib1014">National Comprehensive Cancer Network (NCCN). (2019a). Clinical practice guidelines in oncology: Genetic/familial high-risk assessment: Breast and ovarian&#x2014;version 1.2019. Retrieved on 7/12/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf">www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf</a></p>
<p class="bib" id="bib1015">National Comprehensive Cancer Network (NCCN). (2019b). Clinical practice guidelines in oncology: Genetic/familial high-risk assessment: Colorectal&#x2014;version 1.2019. Retrieved on 7/22/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf">www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf</a></p>
<p class="bib" id="bib1016">National Comprehensive Cancer Network (NCCN). (2019c). Cancer staging guide. Retrieved on 7/20/2019 at: <a href="http://www.nccn.org/patients/resources/diagnosis/staging.aspx">www.nccn.org/patients/resources/diagnosis/staging.aspx</a></p>
<p class="bib" id="bib1017">National Comprehensive Cancer Network (NCCN). (2019d). Clinical practice guidelines in oncology: Breast cancer &#x2013; version 1.2019. Retrieved on 7/17/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf">www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf</a></p>
<p class="bib" id="bib1018">National Comprehensive Cancer Network (NCCN). (2019e). NCCN clinical practice guidelines in oncology: Cutaneous melanoma &#x2013; version 1.2019. Retrieved on 7/2/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf">www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf</a></p>
<p class="bib" id="bib1019">National Comprehensive Cancer Network (NCCN). (2019f). NCCN clinical practice guidelines in oncology: Prostate cancer &#x2013; version 1.2019. Retrieved7/23/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf">www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf</a></p>
<p class="bib" id="bib1020">National Comprehensive Cancer Network (NCCN). (2019g). NCCN clinical practice guidelines in oncology: Antiemesis &#x2013; version 1.2019. Retrieved on 7/19/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf">www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf</a></p>
<p class="bib" id="bib1021">National Comprehensive Cancer Network (NCCN). (2019h). NCCN guidelines for supportive care: Cancer related fatigue &#x2013; version 1.2019. Retrieved on 7/20/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf">www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf</a></p>
<p class="bib" id="bib1022">National Comprehensive Cancer Network (NCCN). (2019i). NCCN clinical practice guidelines in oncology: Distress &#x2013; version 1.2019. Retrieved on 7/11/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/distress.pdf">www.nccn.org/professionals/physician_gls/pdf/distress.pdf</a></p>
<p class="bib" id="bib1023">National Comprehensive Cancer Network (NCCN). (2019j). NCCN clinical practice guidelines in oncology: Prevention and treatment of cancer-related infection&#x2014;version 1.2019. Retrieved on 7/14/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf">www.nccn.org/professionals/physician_gls/pdf/infections.pdf</a></p>
<p class="bib" id="bib1024">National Comprehensive Cancer Network (NCCN). (2019k). NCCN clinical practice guidelines in oncology: Cancer-associated thromboembolic disease &#x2013; version 1.2019. Retrieved on 7/10/2019 at: <a href="http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf">www.nccn.org/professionals/physician_gls/pdf/vte.pdf</a></p>
<p class="bib" id="bib1025">National Institutes of Health, National Center for Complementary and Integrative Health (NCCIH). (2018). Complementary, alternative, or integrative health: What&#x2019;s in a name? Retrieved on 7/12/2019 at: <a href="http://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name">www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name</a></p>
<p class="bib" id="bib1026">Negrin, R. S. (2018). Early and late complications of hematopoietic cell transplantation. UpToDate. Waltham, MA. Retrieved on 7/27/2019 at: <a href="http://www.uptodate.com/contents/early-and-late-complications-of-hematopoietic-cell-transplantation">www.uptodate.com/contents/early-and-late-complications-of-hematopoietic-cell-transplantation</a></p>
<p class="bib" id="bib1027">Negrin, R. S., &#x0026; Bonis, P. A. L. (2019). Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplant. UpToDate. Waltham, MA. Retrieved on7/19/2019 at: <a href="http://www.uptodate.com/contents/diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation">www.uptodate.com/contents/diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation</a></p>
<div class="pagebreak_container"><span class="pagebreak">p. 365</span><div class="rule"></div><span id="page366" class="pagebreak" epub:type="pagebreak" title="366">p. 366</span></div>
<p class="bib" id="bib1028">Neuss, M. N., Gilmore, T. R., Belderson, K. M., et al. (2017). 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. <em>Oncology Nursing Forum</em>, <em>44</em>(1), 31&#x2013;43</p>
<p class="bib" id="bib1029">O&#x2019;Gorman, C., Sasiadek, W., Denieffe, S., et al. (2015). Predicting radiotherapy-related clinical toxicities in cancer: A literature review. <em>Clinical Journal of Oncology Nursing</em>, <em>18</em>(3), 37&#x2013;44.</p>
<p class="bib" id="bib1030">Oktay, K., Harvey, B. E., Partridge, A. H., et al. (2018). Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <em>Journal of Clinical Oncology</em>, <em>36</em>(19), 1994&#x2013;2001.</p>
<p class="bib" id="bib1031">*Overcash, J., Tan, A., &#x0026; Noonan, A. (2018). Factors associated with poor sleep in older women diagnosed with breast cancer. <em>Oncology Nursing Forum</em>, <em>45</em>(3), 359&#x2013;371.</p>
<p class="bib" id="bib1032">Pache, B., H&#x00FC;bner, M., Jurt, J., et al. (2017). Minimally invasive surgery and enhanced recovery after surgery: The ideal combination? <em>Journal of Surgical Oncology</em>, <em>116</em>(5), 613&#x2013;616.</p>
<p class="bib" id="bib1033">Pachmayr, E., Treese, C., &#x0026; Stein, U. (2017). Underlying mechanisms for distant metastasis-molecular biology. <em>Visceral Medicine</em>, <em>33</em>(1), 11&#x2013;20.</p>
<p class="bib" id="bib1034">Rees, I., Jones, D., Chen, H., et al. (2018). Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: A systematic review. <em>Preventive Medicine</em>, <em>111</em>, 323&#x2013;335.</p>
<p class="bib" id="bib1035">Rosell&#x00F3;, S., Blasco, I., Garc&#x00ED;a Fabregat, L., et al. (2017). Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. <em>Annals of Oncology</em>, <em>28</em>(suppl_4), iv100&#x2013;iv118.</p>
<p class="bib" id="bib1036">Ross, M., &#x0026; Fischer-Cartlidge, E. (2017). Scalp cooling. <em>Clinical Journal of Oncology Nursing</em>, <em>21</em>(2), 226&#x2013;233.</p>
<p class="bib" id="bib1037">Rubinsak, L. A., Kang, L., Fields, E. C., et al. (2018). Treatment-related radiation toxicity among cervical cancer patients. <em>International Journal of Gynecologic Cancer</em>, <em>28</em>(7), 1387&#x2013;1393.</p>
<p class="bib" id="bib1038">Rugo, H. S., Melin, S. A., &#x0026; Voigt, J. (2017). Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: Systematic review and meta-analysis. <em>Breast Cancer Research and Treatment</em>, <em>163</em>(2), 199&#x2013;205.</p>
<p class="bib" id="bib1039">Ruiz, A., Sebagh, M., Wicherts, D. A., et al. (2018). Long-term survival and cure model following liver resection for breast cancer metastases. <em>Breast Cancer Research and Treatment</em>, <em>170</em>(1), 89&#x2013;100.</p>
<p class="bib" id="bib1040">Scarborough, B. M., &#x0026; Smith, C. B. (2018). Optimal pain management for patients with cancer in the modern era. <em>CA: A Cancer Journal for Clinicians</em>, <em>68</em>(3), 182&#x2013;196.</p>
<p class="bib" id="bib1041">Schott, S., Vetter, L., Keller, M., et al. (2017). Women at familial risk of breast cancer electing for prophylactic mastectomy: Frequencies, procedures, and decision-making characteristics. <em>Archives of Gynecology and Obstetrics</em>, <em>295</em>(6), 1451&#x2013;1458.</p>
<p class="bib" id="bib1042">Siegel, R. L., Miller, K. D., &#x0026; Jemal, A. (2019). Cancer statistics, 2019. <em>CA: A Cancer Journal for Clinicians</em>, <em>69</em>(1), 7&#x2013;34.</p>
<p class="bib" id="bib1043">*So, W. K., Kwong, A. N., Chen, J. M., et al. (2019). A theory-based and culturally aligned training program on breast and cervical cancer prevention for South Asian community health workers: A feasibility study. <em>Cancer Nursing</em>, <em>42</em>(2), E20&#x2013;E30.</p>
<p class="bib" id="bib1044">*Thorpe, D. M., Conley, S. B., Drapek, L., et al. (2017). Putting evidence into practice: Anorexia. Retrieved on 7/28/2019 at: <a href="http://www.ons.org/pep/anorexia">www.ons.org/pep/anorexia</a></p>
<p class="bib" id="bib1045">United States Environmental Protection Agency (EPA). (2017). Summary of the Occupational Safety and Health Act: 29 U.S.C. &#x00A7;651 et seq. (1970). Retrieved on 7/11/2019 at: <a href="http://www.epa.gov/laws-regulations/summary-occupational-safety-and-health-act">www.epa.gov/laws-regulations/summary-occupational-safety-and-health-act</a></p>
<p class="bib" id="bib1046">U.S. Food and Drug Administration (FDA). (2019). Caution when using robotically-assisted surgical devices in women&#x2019;s health including mastectomy and other cancer-related surgeries: FDA safety communication. Retrieved on 7/26/2019 at: <a href="http://www.fda.gov/medical-devices/safety-communications/caution-when-using-robotically-assisted-surgical-devices-womens-health-including-mastectomy-and-other-cancer-related-surgeries">www.fda.gov/medical-devices/safety-communications/caution-when-using-robotically-assisted-surgical-devices-womens-health-including-mastectomy-and-other-cancer-related-surgeries</a></p>
<p class="bib" id="bib1047">van den Beuken-van Everdingen, M. H., Hochstenbach, L. M., Joosten, E. A., et al. (2016). Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. <em>Journal of Pain and Symptom Management</em>, <em>51</em>(6), 1070&#x2013;1090.</p>
<p class="bib" id="bib1048">van Elsland, D., &#x0026; Neefjes, J. (2018). Bacterial infections and cancer. <em>European Molecular Biology Organization Reports</em>, <em>19</em>(11), e46632.</p>
<p class="bib" id="bib1049">Voog, E., Campion, L., Du Rusquec, P., et al. (2018). Totally implantable venous access ports: A prospective long-term study of early and late complications in adult patients with cancer. <em>Supportive Care in Cancer</em>, <em>26</em>(1), 81&#x2013;89.</p>
<p class="bib" id="bib1050">Wagner, L. I., Zhao, F., Goss, P. E., et al. (2018). Patient-reported predictors of early treatment discontinuation: Treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA. 27 (E1Z03). <em>Breast Cancer Research and Treatment</em>, <em>169</em>(3), 537&#x2013;548.</p>
<p class="bib" id="bib1051">Waldmann, T. A. (2018). Cytokines in cancer immunotherapy. <em>Cold Spring Harbor Perspectives in Biology</em>, <em>10</em>(12), a028472.</p>
<p class="bib" id="bib1052">Wanchai, A., Armer, J. M., Smith, K. M., et al. (2017). Complementary health approaches: Overcoming barriers to open communication during cancer therapy. <em>Clinical Journal of Oncology Nursing</em>, <em>21</em>(6), E287&#x2013;E298.</p>
<p class="bib" id="bib1053">Wang, C., Dickie, J., Sutavani, R. V., et al. (2018). Targeting head and neck cancer by vaccination. <em>Frontiers in Immunology</em>, <em>9</em>, 830, 1&#x2013;12.</p>
<p class="bib" id="bib1054">*Wang, N., Yang, Z., Miao, J., et al. (2018). Clinical management of cancer-related fatigue in hospitalized adult patients: A best practice implementation project. <em>JBI Database of Systematic Reviews and Implementation Reports</em>, <em>16</em>(10), 2038&#x2013;2049.</p>
<p class="bib" id="bib1055">White, L. L., Cohen, M. Z., Berger, A., et al. (2017). Perceived self-efficacy: A concept analysis for symptom management in patients with cancer. <em>Clinical Journal of Oncology Nursing</em>, <em>21</em>(6), E272&#x2013;E279.</p>
<p class="bib" id="bib1056">*Williams, L., Ciccolini, K., Johnson, L. A., et al. (2017). Putting evidence into practice: Skin reactions. Retrieved on 7/23/2019 at: <a href="http://www.ons.org/pep/skin-reactions">www.ons.org/pep/skin-reactions</a></p>
<p class="bib" id="bib1057">*Wilson, B. J., Ahmed, F., Crannell, C. E., et al. (2017). Putting evidence into practice: Preventing infection &#x2013; general. Retrieved on 7/5/2019 at: <a href="http://www.ons.org/pep/prevention-infection-general">www.ons.org/pep/prevention-infection-general</a></p>
<p class="bib" id="bib1058">World Cancer Research Fund (WCRF)/American Institute for Cancer Research. (2018). Diet, nutrition, physical activity and cancer: A global perspective. Retrieved on 7/19/2019 at: <a href="http://www.wcrf.org/dietandcancer">www.wcrf.org/dietandcancer</a></p>
<p class="BIBLIOGRAPHYpREFMGROUPpTITLE">Resources</p>
<p class="bib" id="bib1059">American Association of Cancer Research (AACR), <a href="http://www.aacr.org">www.aacr.org</a></p>
<p class="bib" id="bib1060">American Cancer Society (ACS), <a href="http://www.cancer.org">www.cancer.org</a></p>
<p class="bib" id="bib1061">American College of Surgeons Commission on Cancer (CoC), <a href="http://www.facs.org/quality-programs/cancer/coc">www.facs.org/quality-programs/cancer/coc</a></p>
<p class="bib" id="bib1062">American Pain Society (APS), <a href="http://www.ampainsoc.org">www.ampainsoc.org</a></p>
<p class="bib" id="bib1063">American Society of Clinical Oncology (ASCO), <a href="http://www.asco.org">www.asco.org</a></p>
<p class="bib" id="bib1064">American Society for Radiation Oncology (ASTRO), <a href="http://www.astro.org">www.astro.org</a></p>
<p class="bib" id="bib1065">Association of Oncology Social Work (AOSW), <a href="http://www.aosw.org">www.aosw.org</a></p>
<p class="bib" id="bib1066">Cancer Care, <a href="http://www.cancercare.org/">www.cancercare.org/</a></p>
<p class="bib" id="bib1067">Centers for Disease Control and Prevention (CDC): Cancer Control and Prevention, <a href="http://www.cdc.gov/cancer/">www.cdc.gov/cancer/</a></p>
<p class="bib" id="bib1068">Hospice and Palliative Nurses Association (HPNA), <a href="http://www.hpna.org">www.hpna.org</a></p>
<p class="bib" id="bib1069">LIVESTRONG Survivorship Centers of Excellence, <a href="http://www.livestrong.org">www.livestrong.org</a></p>
<p class="bib" id="bib1070">National Cancer Institute (NCI), <a href="http://www.cancer.gov">www.cancer.gov</a></p>
<p class="bib" id="bib1071">National Coalition for Cancer Survivorship, <a href="http://www.canceradvocacy.org">www.canceradvocacy.org</a></p>
<p class="bib" id="bib1072">National Comprehensive Cancer Network (NCCN), <a href="http://www.nccn.org">www.nccn.org</a></p>
<p class="bib" id="bib1073">National Hospice and Palliative Care Organization, <a href="http://www.nhpco.org">www.nhpco.org</a></p>
<p class="bib" id="bib1074">National Institutes of Health, National Center for Complementary and Integrative Health (NCCIH), <a href="http://nccih.nih.gov">nccih.nih.gov</a></p>
<p class="bib" id="bib1075">OncoLink (cancer resources), <a href="http://www.oncolink.org">www.oncolink.org</a></p>
<p class="bib" id="bib1076">Oncology Nursing Society (ONS), <a href="http://www.ons.org">www.ons.org</a></p>
<p class="bib" id="bib1077">Quackwatch, <a href="http://www.quackwatch.org">www.quackwatch.org</a></p>
<p class="bib" id="bib1078">The Bone Marrow Foundation, <a href="http://bonemarrow.org/">bonemarrow.org/</a></p>
<p class="bib" id="bib1079">The Cancer Support Community, <a href="http://www.cancersupportcommunity.org">www.cancersupportcommunity.org</a></p>
<p class="bib" id="bib1080">The COVID-19 and Cancer Consortium, <a href="http://ccc19.org">ccc19.org</a></p>
<p class="bib" id="bib1081">The Leukemia and Lymphoma Society, <a href="http://www.lls.org">www.lls.org</a></p>
</section>
</div>
</body>
</html>